Serial plaque changes predicting cardiovascular events

Serial plaque changes predicting cardiovascular events - SPECTRE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54890

Enrollment

500

Registered

2020-06-22

Start date

2020-11-23

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis arteriosclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Aged 50 years and older - Underwent CCTA imaging for clinical indications between 2008 and 2014 - Able to provide written informed consent

Exclusion criteria

Exclusion criteria: - Renal insufficiency, defined as eGFR

Design outcomes

Primary

Measure	Time frame
The main parameter to study will be the mean plaque progression measured with follow-up CCTA imaging comparing between patients with and without MACE.	—

Secondary

Measure	Time frame
The secondary study parameters to be studied will be the following: * Number of high risk plaque features, i.e.: o positive remodelling (RI>1.1) o low attenuation plaque (* 30 HU) o spotty calcification o napkin ring sign * Relative mean plaque progression * Difference in non-calcified plaque volume between baseline and follow-up CCTA (delta non-calcified plaque volume) * Difference in calcified plaque volume between baseline and follow-up CCTA (delta calcified plaque volume) * Coronary calcium score * Plasma biomarker expression	—

Measure

Time frame

The secondary study parameters to be studied will be the following: * Number of high risk plaque features, i.e.: o positive remodelling (RI>1.1) o low attenuation plaque (* 30 HU) o spotty calcification o napkin ring sign * Relative mean plaque progression * Difference in non-calcified plaque volume between baseline and follow-up CCTA (delta non-calcified plaque volume) * Difference in calcified plaque volume between baseline and follow-up CCTA (delta calcified plaque volume) * Coronary calcium score * Plasma biomarker expression

—

Countries

Netherlands

Outcome results